Sharps Technology (STSS) said Wednesday it has initiated first shipments of its SecureGard and SoloGard smart safety syringes relating to three client orders from its manufacturing site in Hungary.
The company began shipment of its first commercial order of Sologard to a US-based IV flushing services provider under a previously announced $50 million agreement, while it has also delivered SecureGard syringes to a Hungarian vaccine provider after securing a $100,000 purchase order, Sharps said.
The total purchase commitments reached roughly $500,000 with the two orders, the company said.
The medical device and pharmaceutical packaging company also said it started a 200,000-unit shipment of 1mL low dead-volume syringes to a Switzerland-based global provider of cosmetic, dental, and ophthalmic injectable therapies.
Shares were up more than 53% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。